Anti-BTLA Rabbit Polyclonal Antibody for WB, ELISA - Q7Z6A9

Core Product Specifications and Parameters

Biological Background: BTLA Function and Localization

• B- and T-lymphocyte attenuator (BTLA), also known as CD272 or BTLA1, is a member of the immunoglobulin superfamily and serves as an inhibitory receptor on lymphocytes.
• Negatively regulates antigen receptor signaling by recruiting the phosphatases SHP-1 (PTPN6) and SHP-2 (PTPN11), thereby modulating immune responses. Related references: PMID:12796776 PMID:14652006 PMID:15568026
• Interacts with TNFRSF14 (HVEM) in "cis" (on the same cell) to maintain T cell resting state, or in "trans" (on other cells) to provide survival signals during adaptive immune responses. Related references: PMID:19915044
• Localizes primarily to the cell membrane, consistent with its role as a transmembrane receptor.
• Undergoes post-translational modifications including glycosylation, phosphorylation, and disulfide bond formation, which may influence receptor function.
• The BTLA gene is annotated with "Alternative splicing," suggesting the existence of multiple transcript variants.
• Additional UniProt keywords include 3D-structure, Adaptive immunity, Glycoprotein, Immunoglobulin domain, Phosphoprotein, and Signal, reflecting its structural and immunological roles.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular region (amino acids 31–241) of human BTLA, recognized in Western blot and ELISA applications.
• For Western blot, consider using reduced whole cell lysates from human, mouse, or rat lymphocyte lines, given the antibody's cross-reactivity.
• The predicted molecular weight is 33 kDa; however, post-translational modifications such as glycosylation may result in a higher observed band.
• Validate the antibody in your specific sample system and application context, as performance may vary.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, laboratories, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—from early concept through clinical application. This BTLA antibody, targeting an immune checkpoint receptor, is part of a broad portfolio that includes validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and custom sourcing for rare targets. We help streamline your immunology and oncology diagnostic development with reliable supply and expert support.